171 related articles for article (PubMed ID: 21883393)
1. The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma.
Fujii M; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Oct; 36(7):788-92. PubMed ID: 21883393
[TBL] [Abstract][Full Text] [Related]
2. Subungual keratoacanthoma: analysis of cell proliferation and copy number variation of oncogenes compared with periungual squamous cell carcinoma.
Honma M; Kato N; Hashimoto M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Jan; 36(1):57-62. PubMed ID: 20456385
[TBL] [Abstract][Full Text] [Related]
3. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma.
Batinac T; Zamolo G; Coklo M; Hadzisejdic I; Stemberger C; Zauhar G
Pathol Res Pract; 2006; 202(8):599-607. PubMed ID: 16781827
[TBL] [Abstract][Full Text] [Related]
4. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas.
Melendez ND; Smoller BR; Morgan M
Mod Pathol; 2003 Jan; 16(1):8-13. PubMed ID: 12527707
[TBL] [Abstract][Full Text] [Related]
5. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
Biesterfeld S; Josef J
Anticancer Res; 2002; 22(5):3019-23. PubMed ID: 12530035
[TBL] [Abstract][Full Text] [Related]
6. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma.
Kerschmann RL; McCalmont TH; LeBoit PE
Arch Dermatol; 1994 Feb; 130(2):181-6. PubMed ID: 8304756
[TBL] [Abstract][Full Text] [Related]
7. Cell apoptosis as assessed by M30 expression in keratoacanthoma and squamous cell carcinoma.
Batinac T; Zamolo G; Brumini G; Biljan D; Petranović D; Troselj-Vukić B
Coll Antropol; 2008 Jun; 32(2):499-504. PubMed ID: 18756900
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 10 and Ki-67 nuclear marker expression in keratoacanthoma and squamous cell carcinoma.
Basta-Juzbasić A; Klenkar S; Jakić-Razumović J; Pasić A; Loncarić D
Acta Dermatovenerol Croat; 2004; 12(4):251-6. PubMed ID: 15588557
[TBL] [Abstract][Full Text] [Related]
10. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers.
Slater M; Barden JA
Histopathology; 2005 Aug; 47(2):170-8. PubMed ID: 16045778
[TBL] [Abstract][Full Text] [Related]
11. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
12. Immunoexpression of Bcl-x in squamous cell carcinoma and keratoacanthoma: differences in pattern and correlation with pathobiology.
Tan KB; Lee YS
Histopathology; 2009 Sep; 55(3):338-45. PubMed ID: 19723149
[TBL] [Abstract][Full Text] [Related]
13. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma.
Papadavid E; Pignatelli M; Zakynthinos S; Krausz T; Chu AC
Br J Dermatol; 2001 Oct; 145(4):582-9. PubMed ID: 11703284
[TBL] [Abstract][Full Text] [Related]
14. Assessment of syndecan-1 (CD138) and Ki-67 expression for differentiating keratoacanthoma and squamous cell carcinoma.
Lammoglia-Ordiales L; Toussaint-Caire S; Contreras-Barrera M; Fonte-Avalos V; Rodriguez-Carreón AA; Rivera-Macias S; Dominguez-Cherit J
J Drugs Dermatol; 2013 Mar; 12(3):e53-8. PubMed ID: 23545927
[TBL] [Abstract][Full Text] [Related]
15. The role of p53, Ki-67 and laminin expression in the differential diagnosis of keratoacanthoma and well-differentiated SCC.
Turan G; Altun E; Aslan F; Kulahci O
Indian J Pathol Microbiol; 2019; 62(4):561-565. PubMed ID: 31611440
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 may be useful in differentiating between keratoacanthoma and cutaneous squamous cell carcinoma.
Scola N; Segert HM; Stücker M; Altmeyer P; Gambichler T; Kreuter A
Clin Exp Dermatol; 2014 Mar; 39(2):216-8. PubMed ID: 24524559
[No Abstract] [Full Text] [Related]
17. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin.
Sakiz D; Turkmenoglu TT; Kabukcuoglu F
Pathol Res Pract; 2009; 205(9):589-94. PubMed ID: 19577853
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic markers in the differential diagnosis of keratoacanthoma versus squamous cell carcinoma.
Fernandez-Flores A
Histopathology; 2007 Jan; 50(2):284-5. PubMed ID: 17222261
[No Abstract] [Full Text] [Related]
19. Significance of Ki-67 and p53 immunoexpression in the differential diagnosis of oral necrotizing sialometaplasia and squamous cell carcinoma.
Dadfarnia T; Mohammed BS; Eltorky MA
Ann Diagn Pathol; 2012 Jun; 16(3):171-6. PubMed ID: 22197541
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of ezrin in epithelial skin tumors: cytoplasmic ezrin immunoreactivity in squamous cell carcinoma.
Park HR; Min SK; Min K; Jun SY; Seo J; Kim KH; Choi J
Int J Dermatol; 2010 Jan; 49(1):48-52. PubMed ID: 20465611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
